Cameron Turtle
CIK 1758363 · Chief Executive Officer · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$50.42M
Companies
6
Total Filings
44
Lifetime Open-Market Net
-$17.78M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SYRE | Chief Executive Officer | 597,540 | $80.79 | $48.28M | -$5.94M | 12 | 2026-06-03 |
| DMRA | Director | — | $20.78 | — | $0 | 1 | 2026-03-25 |
| ORKA | Director | — | $69.89 | — | $0 | 1 | 2025-06-03 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Chief Executive Officer | 746,507 | $12.01 | $8.97M | $0 | 1 | 2023-11-27 |
| BBIO | See Remarks | 32,068 | $66.80 | $2.14M | -$3.63M | 15 | 2020-12-29 |
| Eidos Therapeutics, Inc. (EIDX) Delisted | Chief Business Officer | 73,159 | — | — | -$8.21M | 13 | 2020-12-16 |
Recent Filings · Page 2 of 5
44 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-03 | ORKA | Grant (A) | — | $0 | EDGAR |
| 2025-01-17 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2024-02-20 | SYRE | Grant (A) | +400 | $3.9K | EDGAR |
| 2024-02-02 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2023-11-27 | Spyre Therapeutics, Inc. (AGLE) Delisted | Mixed | +723,440 | $0 | EDGAR |
| 2021-01-28 | — | Mixed | −50,699 | $0 | |
| 2020-12-29 | BBIO | Mixed | — | -$1.23M | EDGAR |
| 2020-12-16 | Eidos Therapeutics, Inc. (EIDX) Delisted | Mixed | — | -$2.57M | EDGAR |
| 2020-11-25 | BBIO | Mixed | — | -$150.2K | EDGAR |
| 2020-11-13 | Eidos Therapeutics, Inc. (EIDX) Delisted | Mixed | −14,910 | -$999.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.